GYRE (Gyre Therapeutics) Debt-to-Asset : 0.01 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Debt-to-Asset?

Gyre Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.7 Mil. Gyre Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.9 Mil. Gyre Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $125.4 Mil. Gyre Therapeutics's debt to asset for the quarter that ended in Dec. 2024 was 0.01.

Gyre Therapeutics Debt-to-Asset Historical Data

The historical data trend for Gyre Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Debt-to-Asset Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

0.01

Gyre Therapeutics Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial						-	-	0.02	0.01	0.01

Competitive Comparison of Gyre Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Gyre Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Gyre Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Gyre Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.713	+	0.885)	/	125.406
	=	0.01

Gyre Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.713	+	0.885)	/	125.406
	=	0.01

Gyre Therapeutics (NAS:GYRE) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Gyre Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.